Kaprolac K40

Kaprolac K40 is a topical drug candidate developed by Moberg Pharma AB (formerly Moberg Derma AB) for the treatment of moderate to severe seborrhoeic dermatitis of the scalp. It was developed using the company's proprietary Kaprolac® platform, which is designed to enhance the penetration and efficacy of dermatological treatments. The drug was evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial (Study K40-3) in Sweden, which compared two formulations (K40a and K40b) against a placebo. The primary efficacy endpoint was the sum of erythema and desquamation scores at Week 4. While the specific active ingredient and biological target have not been publicly disclosed, the clinical rationale was based on the formulation's ability to improve skin symptoms with a favorable safety profile.

Brand names

Kaprolac K40

Other names

K40bK-40bK 40b